A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc.
Ruijin Hospital
AstraZeneca
Tesaro, Inc.
Astellas Pharma Inc
National University Hospital, Singapore
Trishula Therapeutics, Inc.
NuCana plc
Ukrainian Society of Clinical Oncology
Eli Lilly and Company
Sun Yat-sen University
Washington University School of Medicine
Case Comprehensive Cancer Center